Category: GLP-1s

Weight loss drugs could prevent sleep apnea, shrink CPAP market

By 2030, between 2.5 million and 3.8 million cases of obstructive sleep apnea can be avoided — a 10.7% reduction in overall prevalence — based on estimates of patients taking Wegoy. 

$5 Ozempic? New study sparks calls for Novo Nordisk to cut prices

While the list price for a monthly supply of Ozempic in the U.S. nears $1,000, new research indicates it could be manufactured for less than $5 per month, sparking calls from lawmakers for Novo Nordisk to lower the price of its blockbuster diabetes and…

Cedars-Sinai confirms surgery risks for patients taking weight loss drugs

Among nearly 1 million patients who underwent upper or lower endoscopy procedures, those prescribed GLP-1s, such as Ozempic or Wegovy, were 33% more likely to experience aspiration pneumonia than other patients. 

Wegovy sidesteps the 'forever drug' problem

Nonadherance seems to be a nonissue for patients taking new weight loss drugs, The New York Times reported March 24. 

3 updates on weight loss drugs

Another off-label use of GLP-1s, a drug class including Ozempic, Mounjaro and Zepbound, is gaining traction among women seeking to prevent pregnancy complications. 

Weight loss drugs alter bariatrics

Some bariatric surgeons are noticing a decrease in referrals because of the increasing popularity of GLP-1s, which mimic a gut hormone that suppresses appetite and makes patients feel full. 

Medicare paves way for weight loss drug coverage: WSJ

Less than two weeks after Novo Nordisk’s weight loss drug Wegovy was approved to reduce the risk of heart attacks and strokes, CMS has issued guidance for Medicare coverage of weight loss drugs, The Wall Street Journal reported March 21. 

Patients turn to weight loss meds to prevent pregnancy complications

Physicians are seeing more women turn to weight loss medications before they become pregnant in hopes of lowering their risks of having a miscarriage and other complications, such as preeclampsia and preterm birth. 

The '3rd generation' of weight loss drugs

Anita Courcoulas, MD, defines GLP-1s as “generation one;” dual GLP-1 and GIPs as the second; and a triple threat of GLP-1, GIP and GCGRs as the third generation of weight loss drugs. 

Zepbound surpasses Wegovy in new prescriptions: Reuters

First-time prescriptions for Eli Lilly’s Zepbound surpassed those for Novo Nordisk’s Wegovy in early March, according to data cited by Reuters.